| Total N = 1456 | |
---|---|---|
 | Surgery | No surgery |
 | 1432 (98.35%) | 24 (1.65%) |
Age, yearsa | 57.604 (11.917) | 80.575 (11.257) |
Charlson comorbidity indexa | 0.325 (0.752) | 0.958 (1.197) |
Initial treatment | Â | Â |
Conservative | 648 (45.25%) | – |
Simple mastectomy | 203 (14.18%) | – |
Radical mastectomy | 38 (2.65%) | – |
Radical modified mastectomy | 46 (3.21%) | – |
Neoadjuvant therapy | 165 (11.52%) | 22 (91.67%) |
Adjuvant therapy | Â | Â |
Chemotherapy1 | 455 (31.77%) | Â |
ACT | 166 (11.59%) | Â |
TAC | 80 (5.59%) | Â |
CMF | 8 (0.56%) | Â |
FEC | 42 (2.93%) | Â |
FEC-Taxane | 41 (2.86%) | Â |
TC | 35 (2.44%) | Â |
Other | 88 (6.15%) | Â |
Radiotherapy (yes) | 1126 (78.63%) | Â |
Hormone therapy | 1146 (80.03%) | Â |
Tamoxifen | 484 (33.8%) | Â |
Tamoxifen +GnRH analogues2 | 50 (3.49%) | Â |
Tamoxifen +Aromatase inhibitors | 12 (0.84%) | Â |
Aromatase inhibitors | 639 (44.62%) | Â |
Others | 26 (1.82%) | Â |
TNM3 | Â | Â |
0 | 135 (9.43%) | 0 |
I | 683 (47.7%) | 2 (8.33%) |
II | 453 (31.63%) | 5 (20.83%) |
III | 134 (9.36%) | 4 (16.67%) |
IV | 18 (1.26%) | 11 (45.83%) |